Search

Author/Creator Aizenbud, Lilach

1. Dermatological adverse events under programmed cell death‐1 inhibitors as a prognostic marker in metastatic melanoma. Issue 10 (9th August 2022)

Authors:
Shreberk‐Hassidim, Rony; Aizenbud, Lilach; Lussheimer, Shalev; Thomaidou, Elena; Bdolah‐Abram, Tali; Merims, Sharon; Popovtzer, Aron; Maly, Alex; Lotem, Michal; Zlotogorski, Abraham
Journal:
Dermatologic therapy
Issue:
Volume 35:Issue 10(2022)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors. Issue 3 (10th March 2023)

Authors:
Caulfield, Jasmine I; Aizenbud, Lilach; Perdigoto, Ana Luisa; Meffre, Eric; Jilaveanu, Lucia; Michalek, Dominika A; Rich, Stephen S; Aizenbud, Yariv; Adeniran, Adebowale; Herold, Kevan C; Austin, Matthew R; Kluger, Harriet
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 11:Issue 3(2023)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Impact of healthcare worker shift scheduling on workforce preservation during the COVID-19 pandemic. (20th December 2020)

Authors:
Kluger, Dan M.; Aizenbud, Yariv; Jaffe, Ariel; Parisi, Fabio; Aizenbud, Lilach; Minsky-Fenick, Eyal; Kluger, Jonathan M.; Farhadian, Shelli; Kluger, Harriet M.; Kluger, Yuval
Journal:
Infection control and hospital epidemiology
Issue:
Volume 41:Number 12(2020)
Page Start:
1443
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗